Compared to matched normal tissue, SNHG3 is upregulated in tumor tissues, such as osteosarcoma [19, 36], glioma [20], ovarian cancer [21], breast cancer [22, 34], hepatocellular carcinoma [23, 24, 35], acute myeloid leukemia [29], non-small-cell lung cancer [30], papillary thyroid carcinoma [31], intrahepatic cholangiocarcinoma [32], and gastric cancer [33], and usually brings poor clinical outcomes, including OS, DFS, RFS, stage, grade, tumor size, distant metastasis, and lymph node metastasis. This evidence concerns the gene SNHG3 and central nervous system cancer.